Cardiovascular risk factors in the metabolic syndrome: Impact of insulin resistance on lipids, hypertension, and the development of diabetes and cardiac events

Reviews in Cardiovascular Medicine

Volumn 6, Issue 4, 2005, Pages 194-205

  Zarich, Stuart W ^a  

^a BRIDGEPORT HOSPITAL   (United States)

Author keywords

Diabetes mellitus; High density lipoprotein cholesterol; Hypertension; Low density lipoprotein cholesterol; Metabolic syndrome

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 6; METOPROLOL; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; PRAVASTATIN; ROSIGLITAZONE; SIMVASTATIN; THIAZOLIDINE DERIVATIVE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN;

BEHAVIOR MODIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY RISK; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIET THERAPY; DISEASE COURSE; DOSE RESPONSE; DRUG MEGADOSE; DRUG RESPONSE; DYSLIPIDEMIA; EARLY DIAGNOSIS; ENZYME ACTIVITY; EXERCISE; GENE EXPRESSION; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIPOLYSIS; LOW DRUG DOSE; METABOLIC SYNDROME X; MONOTHERAPY; MORTALITY; OBESITY; PATHOGENESIS; PREDICTION; PREVALENCE; PRIMARY PREVENTION; PROGNOSIS; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; SEX DIFFERENCE; TREATMENT OUTCOME; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; HUMANS; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; RISK FACTORS; UNITED STATES;

EID: 31144462139     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Kylin E. Studies of the hypertension-hyperglycemia-hyperuricemia syndrome (Studien ueber das hypertonie-hyperglykamie-hyperuirkamiesyndrom). Zentralblatt fuer Innere Medizin. 1923;44:105-127.
2. Reaven G. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
3. Grundy S, Brewer H, Cleeman J, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on scientific issues related to definition. Circulation. 2004;109:433-438.
4. Wilson P, Grundy S. The metabolic syndrome: practical guide to origins and treatment: part I. Circulation. 2003;108:1422-1425.
5. Ford E, Giles W, Dietz W. Prevalence of the metabolic syndrome among US adults. JAMA. 2002;287:356-359.
6. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52: 1210-1214.
7. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;350:2362-2374.
8. McGill HC, McMahan A, Herderick EE, et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation. 2002;105:2712-2718.
9. Narayan K, Boyle J, Thompson T, et al. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290:1884-1890.
10. Ninomiya JK, L'Italien G, Criqui MH, et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation. 2003;109:42-46.
11. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001; 24:683-689.
12. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716.
13. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414-419.
14. Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol. 2004;93: 136-141.
15. Haffner S, Mykkanen L, Festa A, et al. Insulin resistant prediabetic subjects have more atherogenic risk factors than insulin sensitive prediabetic subjects. Circulation. 2000;101:975-980.
16. Haffner SM, Stern MP, Hazuda HP, et al. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 1990:263: 2893-2898.
17. Hu FB, Stampfer MJ, Haffner SM, et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25:1129-1134.
18. Assmann G, Sculte H. The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J. 1988;116:1713-1724.
19. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation. 2003; 108:1541-1545.
20. Grundy SM, Cleeman JI, Bairey-Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227-239.
21. Liao Y, Kwon S, Shaughnessy S, et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care. 2004;27:978-983.
22. Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: The Bruneck Study. Diabetes. 1998;47:1643-1649.
23. McLaughlin T, Abbasi F, Heal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139:802-809.
24. Lorenzo C, Okoloise M, Williams K, et al. The metabolic syndrome as predictor of type 2 diabetes. Diabetes Care. 2003;26:3153-3159.
25. Laaksonen DE, Lakka HM, Niskanen LK, et al. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002;156:1070-1077.
26. The DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397-405.
27. Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance as a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care. 1999;22:920-924.
28. Qiao Q, Pyorala K, Pyorala M, et al. Two hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J. 2002;23:1267-1275.
29. Qiao O, Jousilahti P, Erikson J, Tuomilehto J. Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-up. Diabetes Care. 2003:26:2910-2914.
30. Festa A, D'Agostino R, Hanlet A, et al. Differences in insulin resistance in non-diabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes. 2004;53:1549-1555.
31. Kip KE, Marroquin OC, Kelley DE, et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women. Circulation. 2004;109:706-713.
32. Rutter MK, Meigs JB, Sullivan LS, et al. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation. 2004; 110:380-385.
33. Griffin ME, Marcucci MJ, Cline GW, et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes. 1999;48:1270-1274.
34. Ginsberg HN, Stalenhoef AF. The metabolic syndrome: targeting dyslipidemia to reduce coronary risk. J Cardiovasc Risk. 2003;10: 121-128.
35. Pischon T, Girman C, Hotamisligil G, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291: 1730-1737.
36. Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42-47.
37. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation. 2003;107:391-397.
38. Ridker P, Wilson P, Grundy S. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation. 2004;109:2818-2825.
39. Anand SS, Yi Q, Gerstein H, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation. 2003;108:420-425.
40. Nestel P. Metabolic syndrome: multiple candidate genes, multiple environmental factors - multiple syndromes? Int J Clin Pract. 2003; (suppl 134):3-9.
41. Brunzell JD, Ayyobi AF. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med. 2003;115(suppl 8A):24S-28S.
42. Ginsberg H. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106:453-458.
43. Ginsberg H. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation. 2002;106:2137-2142.
44. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol: a meta-analysis population-based prospective study. J Cardiovasc Risk. 1996;3: 213-219.
45. Lamarche B, Moorjani S, Lupien PHJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation. 1996;94:273-278.
46. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.
47. Bloomfield-Rubins H, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410-418.
48. Vakkilainen J, Steiner G, Ansquer JC, et al. Relationship between low density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease. The Diabetes Atherosclerosis Intervention Study (DAIS). Circulation. 2003;107:1733-1737.
49. FIELD Study Investigators. The effect of fenofibrate on major coronary heart disease events in people with type 2 diabetes: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. American Heart Association Annual Scientific Sessions; 13-16 Nov. 2005; Dallas, TX. [late-breaking trial]
50. BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation. 2000;102:21-27.
51. Tenenbaum A, Motro M, Fisman EZ, et al. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004;109:2197-2202.
52. Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 2001;104: 3046-3051.
53. Sacks FM, Tonkin AM, Craven T, et al. Coronary heart disease in patients with low LDL-cholesterol. Benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation. 2002;105:1424-1428.
54. Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care. 2002;25:1198-1202.
55. Collaborative Atorvastatin Diabetes Study (CARDS). Presented at: 64th ADA Sessions; 2004.
56. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103:357-362.
57. Dormandy JA, Charbonnel B, Eckland DJ, et al. for the PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1779-1289.
58. Freed MI, Ratner R, Marcovina SM, et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol. 2002;90: 947-952.
59. Ridker PM. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-Reactive protein. Rationale and design of the JUPITER trial. Circulation. 2003;108:2292-2297.
60. Scuteri A, Najjar SS, Muller DC, et al. Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. J Am Coll Cardiol. 2004;43:1388-1395.
61. Henry R, Kostense PJ, Spijkerman AMW, et al. Arterial stiffness increases with deteriorating glucose tolerance status. Circulation. 2003;107: 2089-2095.
62. Sesso HD, Buring JE, Rifai N, et al. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290:2945-2951.
63. Chen J, Muntner P, Hamm L, et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med. 2004;140:167-174.
64. Gerstein H, Mann J, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421-426.
65. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43:963-969.
66. Barzilay JI, Pressel S, Davis BR, et al. Risk and impact of incident glucose disorders in hypertensive older adults treated with an ACE inhibitor, a diuretic, or a calcium channel blocker: a report from the ALLHAT trial. Am J Hypertens. 2004;15:1A.
67. Pepine C, Cooper-DeHoff R. Cardiovascular therapies and the risk of diabetes. J Am Coll Cardiol. 2004;44:509-512.
68. Staessen JA, Wang J, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens. 2003;21:1055-1076.
69. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metroprolol European Trial (COMET): randomized controlled trial. Lancet. 2003;362:7-13.
70. Bakris GL, Fonesca V, Katholi RE, et al. for the GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227-2236.
71. Rosner MH, Okusa MD. Combination therapy with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in the treatment of patients with type 2 diabetes mellitus. Arch Intern Med. 2003;163:1025-1029.
72. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens. 2002;20:1461-1464.
73. Fox JC, Leight K, Sutradhar SC, et al. The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy. J Clin Hypertens. 2004;6: 437-444.
74. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet. 2004;363: 2049-2051.
75. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925-930.
76. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
77. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.
78. Esposito K, Pontillo A, DiPalo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women. A randomized trial. JAMA. 2003;289:1799-1804.
79. Centers for Disease Control and Prevention Primary Prevention Working Group. Primary prevention of type 2 diabetes mellitus by lifestyle intervention: implications for health policy. Ann Intern Med. 2004;140:951-957.
80. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
81. Reaven G. Do high carbohydrate diets prevent or attenuate the manifestations (or both) of syndrome X? A viewpoint strongly against. Curr Opin Lipidol. 1997;8:23-27.
82. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res. 1998;2(suppl 6): 51S-209S. Erratum in: Obes Res. 1998;6:464.
83. Erlinger TP, Miller ER III, Charleston J, et al. Inflammation modifies the effects of a reduced-fat low-cholesterol diet on lipids: results from the DASH-sodium trial. Circulation. 2003;108: 150-154.